Objectives-To study the functional outcome in patients with rheumatoid arthritis (RA) who tolerate second line drug therapy for five years.
Remarkably little is known about the impact of drug therapy on the long term functional outcome of patients with rheumatoid arthritis (RA). In the short and medium term, disease modifying antirheumatic drugs (DMARDs) have been shown to reduce the disease activity of RA,'-3 but the crucial question-whether long term DMARD studies are blighted by the poor side effect profile of the available DMARDs, such that a minority of patients continue on any drug for as long as five years;6 (c) the 'natural history' of patient function in the absence of drug therapy is not known. Function is likely to decline in the long term for reasons unrelated to the rheumatoid disease process, including ageing and comorbidity.
Sulphasalazine (SASP), penicillamine (PCM), and intramuscular gold sodium thiomalate (gold) are used in the treatment of rheumatoid arthritis. Their efficacy in controlling disease activity has been established in double blind, placebo controlled trials.' There is some evidence that gold' and SASP7 also slow radiological progression, but very little is known about functional outcome in patients treated with these drugs for long periods. This report is an observational study of 675 patients originally enrolled in prospective, controlled studies from a single unit. Years of therapy Figure 1 Changes in measures ofdisease activity overfive years of therapy. n = Number ofpatientsfor whom the measure was available. ESR = Erythrocyte sedimentation rate; CRP = C reactive protein.
only reached significance with pain score (K-W, p < 0 001) and HAQ score (K-W, p<002). There were highly significant improvements in all measures of disease activity in the patients continuing treatment (paired Wilcoxon, all variables p < 0.001). The improvement was maximal at one year, and disease activity was controlled throughout the five year period (fig 1) . HAQ score decreased significantly between years 0 and 1 (p < 0 0001); between year 1 and year 5, the score increased significantly (p < 0 00 1), but at five years it was still significantly lower than before treatment started (p < 0 0001) (fig 2) .
Subgroup analysis showed there were no significant differences in age, sex, or disease duration between the patients treated with SASP, PCM, or gold. At the start of treatment the groups were well matched for pain score, morning stiffness and ESR, but the gold group had a significantly lower HAQ score (2-0 v 2-25 (PCM) v 2-33 (SASP); K-W, p < 0 05), Porter, McInnes, Hunter, Capell these patients (fig 1) . However, because it is our -policy to consider changing DMARD therapy in patients with persistent (or recrudescent) disease activity (in an attempt to achieve better control of their RA), it is possible that those patients continuing to receive therapy may simply represent a group who tolerate therapy, and enter natural remission-that is, the improvements seen may not be the result of their DMARD therapy.
This seems unlikely, for two reasons: first, patients who have their DMARD therapy withdrawn almost invariably relapse; second, we have previously demonstrated that only a very small minority of our patients treated with placebo show a substantial improvement in disease activity over six months.'8 It probably is true that the functional outcome of these patients represents the best we can achieve with these drugs, and this emphasises the need for a multidisciplinary approach to the treatment of RA, involvng drug therapy, physiotherapy, occupational therapy, and surgery. This study does not address the outcome of treatment in patients who did not tolerate their assigned therapy, or who had their therapy changed because of inefficacy. It does seem likely that patients who have their DMARD therapy changed because of poor control of disease activity are likely to have a worse outcome, but it is possible that patients who develop side effects from one DMARD may fare no worse, if the subsequently tolerate a different DMARD long term. Data from a group of 123 patients followed up for 10 years lend support to this supposition. ' The comparisons of gold, PCM and SASP show a strikingly similar response over the first year of therapy, and very similar results over the five year period. Over five years, area under the curve analysis showed that ESR and morning stiffness improved more in the gold group, suggesting that gold therapy may be more effective in suppressing disease activity in the long term. However, multiple statistical analyses were performed, and the potential dangers of subgroup analyses are well recognised. The greater improvement in articular index with PCM might be because this group started with a higher articular index (22 v 14 (gold) v 19 (SASP); K-W, p < 0001). There is some evidence that better control of the ESR over several years is correlated with reduced radiological progression,14 15 and this suggests that if the lower ESR in the gold group is a true effect, it could be of clinical significance. In contrast, there were no differences between the groups in functional outcome after five years, suggesting that any superiority of gold over PCM and SASP is marginal, and of limited clinical significance.
The percentage of patients tolerating DMARD therapy in this study compares favourably with previous studies. Previous studies have found that SASP is continued in 27% of patients'0 for two-years, and in 19-22% for five years,20 compared with 26% of patients continuing SASP therapy for five years in this study. Similar results have been found with PCM, 31/% of patients continuing therapy for two years,20 and 17% for five years,6 compared with 22% in this study. The most striking difference from the literature is our result with gold therapy-the percentage of patients continuing gold over five years has been reported by Situnayake et a16 to be as low as 8%, compared with 34% of our patients. One of the reasons for this discrepancy is that very few patients stopped gold therapy because of inefficacy in our study, but 29-5% of patients stopped gold for this reason in the study by Situnayake. Bendix et a12' found that 31% of patients continued gold for more than four years. This study demonstrates that it is possible to maintain a larger number of patients on long term gold therapy, with demonstrable sustained benefit, than was previously thought possible.
Conclusion
This study has provided evidence for the long term efficacy of DMARD therapy. Good control of disease activity and improved function were achieved for five years in approximately 30% of patients with active RA. The improvement in functional abilities suggests a possible effect on disease outcome, in addition to disease process. Toxicity remains a major problem, such that a minority of patients tolerate gold, SASP, or PCM for five years, but more patients can be maintained on long term DMARD therapy than has previously been reported. In the absence of curative therapy for severe RA, the significant amelioration of disease achieved with the judicious use of DMARDs is worthy of emphasis.
rheumatoid arthritis. 
Outcome of second line therapy in

